Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Acetate

FDA-approved product (injectable, injection), marketed as Carmol Hc, Cortef Acetate, Cortifoam and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Inflammation
  • Pruritus
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Hydrocortisone Acetate reaches ≥40% AI-predicted activity against MRSA, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

    NCT05685615 · start 2023-04-20

    Registered record
    Registry ID
    NCT05685615
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    BV100 plus Polymyxin B; BAT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-04-20
    Completion
    2024-12-11
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionBV100 plus Polymyxin B; BAT
    PhasePhase 2
    Registry statusCompleted

  • Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection

    NCT06570850 · start 2023-04-01

    Registered record
    Registry ID
    NCT06570850
    Conditions
    Infection Due to Carbapenem Resistant Acinetobacter
    Interventions
    Colistin Sodium Methanesulfonate; Colistin Sodium Methanesulfonate plus Fosfomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-04-01
    Completion
    2025-07
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Due to Carbapenem Resistant Acinetobacter
    InterventionColistin Sodium Methanesulfonate; Colistin Sodium Methanesulfonate plus Fosfomycin
    PhasePhase 4
    Registry statusUnknown

  • The Effect of Curcumin Against Colistin-induced Nephrotoxicity

    NCT05613361 · start 2023-01-01

    Registered record
    Registry ID
    NCT05613361
    Conditions
    Acute Kidney Injury; Drug-Induced Nephropathy
    Interventions
    Colistin; Curcumin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-01-01
    Completion
    2024-10-30
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury; Drug-Induced Nephropathy
    InterventionColistin; Curcumin
    PhasePhase 3
    Registry statusUnknown

  • Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections

    NCT05258851 · start 2022-06-01

    Registered record
    Registry ID
    NCT05258851
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    Ceftazidime-avibactam; Colistin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-06-01
    Completion
    2024-01-28
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    InterventionCeftazidime-avibactam; Colistin
    PhasePhase 3
    Registry statusTerminated

  • Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients

    NCT05279586 · start 2022-03

    Registered record
    Registry ID
    NCT05279586
    Conditions
    Hepatic Encephalopathy
    Interventions
    lactulose; colistin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2022-03
    Completion
    2023-03
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy
    Interventionlactulose; colistin
    PhaseEarly phase 1
    Registry statusUnknown

  • Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.

    NCT04995133 · start 2021-07-14

    Registered record
    Registry ID
    NCT04995133
    Conditions
    Hospital Infection; Multi-antibiotic Resistance; Critically Ill
    Interventions
    Colistin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-07-14
    Completion
    2022-01-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital Infection; Multi-antibiotic Resistance; Critically Ill
    InterventionColistin
    PhasePhase 4
    Registry statusUnknown

  • A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

    NCT04208763 · start 2019-12-20

    Registered record
    Registry ID
    NCT04208763
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Imipenem; Tigecycline; GMCSF; Colistin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-12-20
    Completion
    2021-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionImipenem; Tigecycline; GMCSF; Colistin
    PhaseNot applicable
    Registry statusUnknown

  • Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae

    NCT04489459 · start 2019-09-21

    Registered record
    Registry ID
    NCT04489459
    Conditions
    Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae
    Interventions
    Colistin; Meropenem; Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-09-21
    Completion
    2020-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae
    InterventionColistin; Meropenem; Tigecycline
    PhasePhase 4
    Registry statusUnknown

  • ANTIBIOTIC-RESISTANT ENTEROBACTERALES BLOODSTREAM INFECTIONS AND RISK FACTORS IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT

    NCT07172932 · start 2019-09-01

    Registered record
    Registry ID
    NCT07172932
    Conditions
    Bloodstream Infections; Enterobacteriaceae Infections; Intensive Care (ICU); Antibiotic Resistant Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-09-01
    Completion
    2023-01-30
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBloodstream Infections; Enterobacteriaceae Infections; Intensive Care (ICU); Antibiotic Resistant Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • 7-days Versus 14 Days of Antibiotics Therapy for Ventilator Associated Pneumonia

    NCT03477292 · start 2018-03-01

    Registered record
    Registry ID
    NCT03477292
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    Duration of antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-03-01
    Completion
    2024-12-31
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionDuration of antibiotic
    PhaseNot applicable
    Registry statusCompleted

  • Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

    NCT03460704 · start 2018-01-29

    Registered record
    Registry ID
    NCT03460704
    Conditions
    Non Cystic Fibrosis Bronchiectasis
    Interventions
    CMS; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-01-29
    Completion
    2022-03-15
    Enrolment
    287

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Cystic Fibrosis Bronchiectasis
    InterventionCMS; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Expanded Quantitative Urinary Culture (EQUC) vs Standard Culture (SUC) Techniques in the Clinical Care

    NCT03190421 · start 2017-06-15

    Registered record
    Registry ID
    NCT03190421
    Conditions
    Urinary Tract Infections
    Interventions
    Expanded Urinary Culture; Standard Urine Culture (SUC)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-06-15
    Completion
    2020-04-30
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionExpanded Urinary Culture; Standard Urine Culture (SUC)
    PhaseNot applicable
    Registry statusCompleted

  • Assessment of Kidney Function for Drug Dosage Adjustments in Critically Ill Patients

    NCT03045692 · start 2017-02-13

    Registered record
    Registry ID
    NCT03045692
    Conditions
    ICU Patients
    Interventions
    kidney function assessment by 4 hour creatinine clearance; kidney function assessment by creatinine based eGFR
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-02-13
    Completion
    2019-04-30
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionICU Patients
    Interventionkidney function assessment by 4 hour creatinine clearance; kidney function assessment by creatinine based eGFR
    PhaseNot applicable
    Registry statusUnknown

  • Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

    NCT02894684 · start 2017-01

    Registered record
    Registry ID
    NCT02894684
    Conditions
    Cystic Fibrosis; Infection; Pseudomonas
    Interventions
    Aztreonam; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01
    Completion
    2019-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Infection; Pseudomonas
    InterventionAztreonam; Standard Care
    PhasePhase 4
    Registry statusCompleted

  • Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

    NCT03397914 · start 2017-01

    Registered record
    Registry ID
    NCT03397914
    Conditions
    Gram-Negative Bacterial Infections; Pediatric Cancer; Colistin; Colistin Adverse Reaction; MIC
    Interventions
    Colistimethate Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01
    Completion
    2019-03
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Negative Bacterial Infections; Pediatric Cancer; Colistin; Colistin Adverse Reaction +1 more
    InterventionColistimethate Sodium
    PhasePhase 4
    Registry statusCompleted